Welcome to our dedicated page for Alpha Cognition SEC filings (Ticker: ACOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Alpha Cognition’s clinical-stage disclosures can feel like decoding biotech jargon: pipeline milestones buried in 10-K footnotes, R&D burn rates scattered across 10-Qs, and insider drug-trial optimism hidden in Form 4 exhibits. Investors tracking the company’s Alzheimer’s and mTBI therapy candidates need answers fast.
Stock Titan’s AI reads every Alpha Cognition SEC filing the moment it hits EDGAR, then delivers plain-English explanations. Want to monitor “Alpha Cognition insider trading Form 4 transactions” or need “Alpha Cognition Form 4 insider transactions real-time”? Our platform highlights each executive stock move and links it to trial timelines. Curious about an “Alpha Cognition quarterly earnings report 10-Q filing” or an “Alpha Cognition 8-K material events explained” after pivotal data drops? One click pulls up AI-powered summaries, ratio breakdowns, and trend charts, turning dense disclosures into clear insight.
From the “Alpha Cognition annual report 10-K simplified” to the “Alpha Cognition proxy statement executive compensation,” every document is tagged, searchable, and updated in real time. Use AI-generated overviews to understand cash runway, phase-progress checkpoints, and royalty obligations without wading through pages of technical language. Analysts rely on our tools to compare quarter-over-quarter R&D spend, identify “Alpha Cognition executive stock transactions Form 4,” and perform an “Alpha Cognition earnings report filing analysis” before making decisions. Whether you’re “understanding Alpha Cognition SEC documents with AI” or simply checking the latest filings, Stock Titan lets you spend minutes—not hours—getting the full story behind this neurodegeneration-focused biotech.
Alpha Cognition Inc. is registering securities on Form S-3 and discloses recent commercial, licensing and corporate developments. The company announced the commercial launch of ZUNVEYL (benzgalantamine) on March 19, 2025, a U.S.-approved treatment for mild-to-moderate Alzheimer’s disease. On January 8, 2025, Alpha Cognition entered an exclusive license with China Medical System Holdings Limited covering Asia (ex-Japan), Australia and New Zealand with aggregate deal terms of $44 million, including $6 million in upfront payments and eligibility for royalties; CMS will handle regulatory, development, manufacturing and commercialization in those territories. On January 14, 2025 the company made four strategic commercial and medical hires. As of August 22, 2025, several European, Canadian and Australian patents derived from WO2009127218 and WO2014016430 are abandoned or in the process of abandonment. Financial disclosure items include net tangible book value per share of $1.97 as of June 30, 2025, and material potential dilution from warrants, preferred conversions and options (multi-million share totals disclosed).
Alpha Cognition director Robert Wills purchased 15,000 shares of common stock in open market transactions on 08/18/2025. The filing shows a weighted average price of $8.4885 per share, with individual trade prices ranging from $8.15 to $8.86. After the purchases the reporting person beneficially owns 15,000 shares. The Form 4 was filed by one reporting person and identifies the purchase as an open market acquisition; the filer agrees to provide transaction-level price details on request.
Alpha Cognition director Phillip Joseph Mertz reported a sale of 27,778 common shares on 08/18/2025 at a reported price of $9 per share. After the transaction he beneficially owns 22,462 shares directly and 12,560 shares indirectly through Mertz Holdings. The Form 4 includes a standard disclaimer that the reporting person disclaims beneficial ownership except to the extent of pecuniary interest, and it is signed by Phillip Mertz on 08/20/2025.
Leonard Mertz, a director of Alpha Cognition Inc. (ACOG), reported insider transactions dated 08/18/2025. The filing shows a purchase of 27,778 common shares at $9.00 per share and a separate disposition of 138,495 common shares. After the purchase, 121,503 shares were reported as beneficially owned indirectly by The Len Mertz Trust. The Form 4 is signed 08/20/2025.
FAQ
What is the current stock price of Alpha Cognition (ACOG)?
What is the market cap of Alpha Cognition (ACOG)?
